Carboplatin-induced Nephrotoxicity in Ovarian, fallopian tube and primary peritoneal Cancer Patients N-acetylcysteine, Carboplatin, Nephrotoxicity
Conditions
Interventions
Standard Carboplatin containing chemotherapy regimen for a total of 4 cycles.,The experimental group will receive oral N-acetylcysteine at a dose of 1,200 mg per day. The medication will be started on
Active Comparator Drug,Experimental Drug
Carboplatin containing chemotherapy,N-acetylcysteine plus Carboplatin containing chemotherapy
Sponsors
Rajavithi Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. 2.Received first-line chemotherapy with a Carboplatin-containing regimen and completed four cycles of chemotherapy at Rajavithi Hospital.
Exclusion criteria
Exclusion criteria: 1.Allergy to N-acetylcysteine or Carboplatin. 2.Requirement to change treatment to another regimen (e.g., change in chemotherapy regimen). 3.Patients who previously received chemotherapy or radiotherapy. 4.Pregnant or breastfeeding women. 5.Patients with pre-existing kidney disease prior to chemotherapy. 6.Patients using medications or dietary supplements that may affect renal function before or during chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Carboplatin induced nephrotoxicity During 4 cycle of chemotherapy Kidney Disease: Improving Global Outcomes (KDIGO) | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life During 4 cycle of chemotherapy Functional Assessment of Cancer Therapy - Ovarian (FACT-O) Scoring Guidelines, version 4,Adverse events During 4 cycle of chemotherapy National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03 (CTCAE) | — |
Countries
Thailand
Contacts
Public ContactSucharee Yaranun
Rajavithi hospital, department of obstetrics and gynecology
Outcome results
None listed